MINNEAPOLIS (Jan. 29, 2025) -- Peytant Solutions Inc., a medical technology company pioneering the use of amnion-based covered scaffolds for the treatment of luminal disease, announces the appointment of Craig Walker, MD as Chief Medical Officer. Dr. Walker, a globally recognized key opinion leader, joins Peytant with a distinguished combination of clinical practice, medical research, and product development experience and will oversee all current and future clinical applications of Peytant’s initial flagship product, the AMStent® Tracheobronchial Covered Stent System.
Dr. Walker is
board certified in internal medicine, cardiovascular disease, and
interventional cardiology. He is a fellow of the American College of Cardiology,
American College of Physicians, American
Society of Cardiovascular Interventionists, International College of Angiology,
Society for Cardiac Angiography and Interventions, American College of Chest Physicians, and Council on Clinical Cardiology. He attended Nicholls State University on academic scholarship and LSU Medical School in New
Orleans. He completed a cardiology fellowship at Ochsner Foundation Hospital,
where he was one of the first interventional fellows in the U.S. Dr. Walker
subsequently performed a research fellowship at Harvard’s Brigham
and Women’s Hospital in Boston.
Dr. Walker is founder
of New Cardiovascular Horizons, which provides multidisciplinary accredited
conferences to advance the field of cardiovascular care. “It is my honor to have Dr.
Walker join our executive management team as our Chief Medical Officer. Over
the past three decades, I have had the privilege of collaborating and
innovating with Dr. Walker on interventional technologies that have improved
patient care. He’s a dedicated and curious scientist, real world physician, and
successful entrepreneur with an unwavering commitment to improving the medical
care,” stated John Schorgl, Peytant Solutions’ Chairman and Chief
Executive Officer.
“The AMStent system is a first-of-its-kind stent with an
amnion-based covering to treat bronchial obstructions. I am optimistic that it
will improve outcomes in patients with bronchial obstructions and I look
forward to objectively assessing outcomes in patients and further evaluating
additional clinical applications,” said Dr. Walker.
The U.S. Food and Drug Administration (FDA) granted
marketing authorization (clearance to market in the U.S. as a Class II device)
for the AMStent® Tracheobronchial Covered Stent System in October 2024. The
initial indication for the AMStent system is for use in the treatment of
tracheobronchial strictures produced by malignant neoplasms in adult patients.
The AMStent system is designed to treat pulmonary
obstructions caused by cancer. In the U.S., lung cancer is the leading cause
of cancer deaths, accounting for about one in five of all cancer deaths. Many
patients with cancer in the lung develop malignant airway obstructions as the
disease progresses. Palliative care is often pursued by increasing airflow in
the trachea or tracheobronchial tree through dilation of the lumen. Once
airflow is restored, it is routine to place airway stents in the passageway.
The benefits of the AMStent system, as seen in validation data, include reduced
migration, reduced local inflammation and granuloma formation, and reduced
mucus accumulation and occlusion – so important to achieving the desired
palliative relief for the patient.
About Peytant Solutions, Inc. Peytant is a
medical technology manufacturer seeking to improve outcomes for patients with
luminal blockages. Minneapolis-based Peytant is focused on commercializing the
AMStent® Tracheobronchial Covered Stent System, a platform technology
comprising an amnion-based covered stent and catheter delivery system.
Peytant's AMStent system is the first step toward transforming the treatment of
luminal diseases.
